Research & Development
Mirum Pharmaceuticals collaborates with EVERSANA
16 October 2020 -

Mirum Pharmaceuticals Inc (Nasdaq: MIRM), a biopharmaceutical company, has collaborated with EVERSANA, a company that provides commercial services to the life science industry, it was reported on Thursday.

The collaboration is aimed at EVERSANA leading the United States market access, distribution and patient services for Mirum's maralixibat.

The product is a novel, minimally absorbed, orally administered apical sodium dependent bile acid transporter inhibitor that is being assessed for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). Mirum initiated its rolling New Drug Application (NDA) to the US Food and Drug Administration (FDA) in August 2020, and expects to complete the NDA submission in the first quarter of 2021, and is preparing for launch in the second half of 2021.

Mirum is to use EVERSANA's commercialisation platform to provide integrated nationwide distribution, specialty pharmacy, patient services and Hub support for maralixibat, if approved.

Login
Username:

Password:


Related Headlines